However which way a future deal would transpire, the change in...

However which way a future deal would transpire, the change in strategy last year and approximate confluence next year of:

1. P2b trial results
2. Tox study results
3. possible FDA accelerated approval and PRV
4. Exondys 51 patent expiry 2025



… seems to suggest we are doing final reno work on the house before putting it on the market.

If it’s worth $110 million to a drug company to get 4 months of earlier sales (PRV), then adding 19 years of protection to Exondys 51 (to name just one drug) through a combo patent could be worth $6 bill to Sarepta.

If you switch off every time I mention the word “patent”, imho intellectual property means nearly EVERYTHING to a pharma company.

Hence George Tachas’ value to ANP.

Add to that the possible ending of the Ionis licensing agreement (total conjecture but hard to imagine there isn’t an escape clause for ANP given no Ionis IP protection now and no new drugs for 20 or so years).